Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02908074 | A 6 Month Safety Extension Study of MBGS205 | PHASE2 | COMPLETED | 143 | — | — | Nov 1, 2016 | Nov 1, 2018 | May 17, 2023 | - | — |
| NCT02730169 | Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism | PHASE2 | COMPLETED | 271 | — | — | May 1, 2016 | May 1, 2018 | Sep 13, 2022 | - | — |
| Name | Type | Description |
|---|---|---|
| BGS649 | DRUG | Capsules will be taken weekly for a maximum of 24 weeks |
| Placebo | DRUG | Capsules were taken weekly for a maximum of 24 weeks |